XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1

Note 12 - Segment Information (Tables)

9 Months Ended

Dec. 31, 2024

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

		Three Months Ended December 31,								Nine Months Ended December 31,
		2024				2023				2024				2023
Revenues (a):
Sterilization and Disinfection Control (b)		$	23,507			$	19,338			$	68,669			$	52,345
Clinical Genomics			12,667				12,546				35,570				41,464
Biopharmaceutical Development			12,237				9,430				36,112				28,526
Calibration Solutions			14,429				12,159				38,492				34,948
Total revenues		$	62,840			$	53,473			$	178,843			$	157,283
Gross profit:
Sterilization and Disinfection Control (b)		$	16,461			$	13,951			$	47,191			$	38,018
Clinical Genomics			6,948				6,449				19,344				20,904
Biopharmaceutical Development			7,539				5,841				22,665				17,783
Calibration Solutions			8,806				7,212				23,258				20,050
Reportable segment gross profit			39,754				33,453				112,458				96,755
Corporate and other (c)			-				(51	)			-				(61	)
Gross profit		$	39,754			$	33,402			$	112,458			$	96,694
Reconciling items:
Operating expense			33,975				33,469				97,591				97,485
Operating income (loss)			5,779				(67	)			14,867				(791	)
Non-operating expense (income), net			7,996				(2,013	)			9,367				(475	)
(Loss) earnings before income taxes		$	(2,217	)		$	1,946			$	5,500			$	(316	)

Schedule of Depreciation and Amortization Expense [Table Text Block]

		December 31,				March 31,
		2024				2024
Sterilization and Disinfection Control		$	5,728			$	7,014
Clinical Genomics			10,709				11,813
Biopharmaceutical Development			5,853				6,304
Calibration Solutions			5,832				7,544
Total Inventories		$	28,122			$	32,675

X

- Definition

Tabular display of the depreciation and amortization recorded during the periods for reportable segments.

+ References

No definition available.

+ Details

Name:	mlab_ScheduleOfDepreciationAndAmortizationExpenseTableTextBlock
Namespace Prefix:	mlab_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration